dc.contributor.author
Matricardi, Paolo Maria
dc.contributor.author
Dal Negro, Roberto Walter
dc.contributor.author
Nisini, Roberto
dc.date.accessioned
2022-03-07T10:00:03Z
dc.date.available
2022-03-07T10:00:03Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/34338
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-34055
dc.description.abstract
The natural history of COVID-19 caused by SARS-CoV-2 is extremely variable, ranging from asymptomatic or mild infection, mainly in children, to multi-organ failure, eventually fatal, mainly in the eldest. We propose here the first model explaining how the outcome of first, crucial 10-15 days after infection, depends on the balance between the cumulative dose of viral exposure and the efficacy of the local innate immune response (natural IgA and IgM antibodies, mannose-binding lectin). If SARS-CoV-2 runs the blockade of this innate immunity and spreads from the upper airways to the alveoli in the early phases of the infections, it can replicate with no local resistance, causing pneumonia and releasing high amounts of antigens. The delayed and strong adaptive immune response (high-affinity IgM and IgG antibodies) that follows, causes severe inflammation and triggers mediator cascades (complement, coagulation, and cytokine storm), leading to complications often requiring intensive therapy and being, in some patients, fatal. Low-moderate physical activity can still be recommended. However, extreme physical activity and oral breathing with hyperventilation during the incubation days and early stages of COVID-19 facilitates re-inhalation and early direct penetration of high numbers of own virus particles in the lower airways and the alveoli, without impacting on the airway's mucosae covered by neutralizing antibodies ("viral auto-inhalation" phenomenon). This allows the virus to bypass the efficient immune barrier of the upper airway mucosa in already infected, young, and otherwise healthy athletes. In conclusion, whether the virus or the adaptive immune response reaches the lungs first is a crucial factor deciding the fate of the patient. This "quantitative and time-/sequence-dependent" model has several implications for prevention, diagnosis, and therapy of COVID-19 at all ages.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
immunoglobulin M
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The first, holistic immunological model of COVID‐19: Implications for prevention, diagnosis, and public health measures
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/pai.13271
dcterms.bibliographicCitation.journaltitle
Pediatric Allergy and Immunology
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
454
dcterms.bibliographicCitation.pageend
470
dcterms.bibliographicCitation.volume
31
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32359201
dcterms.isPartOf.issn
0905-6157
dcterms.isPartOf.eissn
1399-3038